中東およびアフリカの IgA 腎症市場、疾患タイプ別 (原発性 IgA 腎症および続発性 IgA 腎症)、症状 (血尿、タンパク尿、浮腫など)、タイプ別 (診断および治療)、人口タイプ別 (小児科および成人)、投与経路別 (経口、非経口など)、エンドユーザー別 (病院、診療所、在宅医療など)、流通チャネル別 (直接入札、病院薬局、小売薬局、オンライン薬局など)、国別 (サウジアラビア、南アフリカ、UAE、イスラエル、クウェート、エジプト、その他の中東およびアフリカ) 業界動向および 2028 年までの予測
市場分析と洞察：中東およびアフリカの IgA 腎症市場
IgA腎症市場は、2021年から2028年の予測期間に市場成長が見込まれています。データブリッジマーケットリサーチは、市場は2021年から2028年の予測期間に18.6％のCAGRで成長し、2028年までに3,269万米ドルに達すると分析しています。IgA腎症に対する新薬の発見の増加は、予測期間における市場の需要を牽引する主な要因です。IgA腎症疾患の増加は疾患の負担の増加につながり、診断および治療製品の需要を増加させるため、IgA腎症市場の成長の原動力として機能します。
IgA 腎症はベルガー病とも呼ばれ、腎臓に IgA 沈着物が蓄積することで起こる腎臓疾患で、炎症を起こし、腎臓組織に損傷を与えます。IgA などの抗体は、細菌やウイルスなどの異物から体を守るために免疫系によって生成されるタンパク質です。この疾患の合併症は ESKD であり、治療には透析が必要になります。
IgA腎症を標的としたパイプライン薬の増加により、潜在的な候補薬がIgA腎症治療の有効性を示すことが可能となり、IgA腎症市場の推進力として機能します。IgA腎症の治療費は、償還がない場合には患者の自己負担を増加させるため、IgA腎症市場の成長の抑制要因となります。医薬品開発における市場プレーヤーの協力により、市場での存在感と革新性が高まり、IgA腎症市場の成長の機会となります。IgA腎症の治療に伴う副作用と免疫抑制剤市場へのCOVID-19の影響は、IgA腎症市場の成長に対する課題となります。
IgA 腎症市場レポートでは、市場シェア、新開発、製品パイプライン分析、国内および現地の市場プレーヤーの影響の詳細、新たな収益源、市場規制の変更、製品承認、戦略的決定、製品発売、地理的拡大、市場における技術革新の観点から見た機会の分析が提供されます。分析と IgA 腎症市場のシナリオを理解するには、アナリスト概要について Data Bridge Market Research にお問い合わせください。当社のチームが、希望する目標を達成するための収益影響ソリューションの作成をお手伝いします。
IgA腎症の市場範囲と市場規模
IgA 腎症市場は、疾患の種類、症状、タイプ、人口タイプ、投与経路、エンドユーザー、流通チャネルに基づいてセグメント化されています。セグメント間の成長は、ニッチな成長分野と市場へのアプローチ戦略を分析し、コアアプリケーション領域とターゲット市場の違いを決定するのに役立ちます。
- 疾患の種類に基づいて、IgA腎症市場は、原発性IgA腎症と続発性IgA腎症に分類されます。2021年には、原発性IgA腎症の発症率が高く、血液検査や尿検査で簡単に診断できるため、原発性IgA腎症セグメントが市場を支配すると予想されます。
- 症状に基づいて、IgA腎症市場は、血尿、タンパク尿、浮腫などに分類されます。2021年には、血尿セグメントが市場を支配すると予想されます。これは、臨床検査で最も一般的かつ頻繁に使用されるパラメーターであり、尿中の血液の量によって検出され、腎臓の病気の発生を示すためです。
- タイプに基づいて、IgA腎症市場は診断と治療に分割されます。2021年には、治療の前にIgA腎症の適切な検出と追跡が必要であり、これは血液や尿検査などの一次検出と腎生検による確認検出によってのみ可能であり、このセグメントが支配的となる主な要因であるため、診断セグメントが市場を支配すると予想されます。
- 人口タイプに基づいて、IgA腎症市場は小児科と成人に分類されます。2021年には、この疾患と老化との関連が研究で示されたため、成人セグメントが大幅な成長を示すことが予想されます。
- 投与経路に基づいて、IgA腎症市場は経口、非経口、その他に分類されます。2021年には、州間取引で入手可能な経口製品ポートフォリオの多様性により、このセグメントの市場が拡大し、経口セグメントが市場を支配すると予想されます。
- エンドユーザーに基づいて、IgA腎症市場は病院、診療所、在宅医療、その他に分類されます。2021年には、強力な財務構造により病院セグメントが市場を支配すると予想されます。
- 流通チャネルに基づいて、IgA腎症市場は、直接入札、病院薬局、小売薬局、オンライン薬局などに分類されます。2021年には、直接入札セグメントが収益の成長を加速させるとともに、税制上の優遇措置も提供しているため、直接入札セグメントはここ数年間繁栄しており、今後、市場のさらなる成長が期待されます。
中東およびアフリカの IgA 腎症市場の国別分析
中東およびアフリカの IgA 腎症市場が分析され、市場規模の情報は、上記の国、病気の種類、症状、種類、人口の種類、投与経路、エンドユーザー、流通チャネル別に提供されます。
中東およびアフリカの IgA 腎症市場レポートで取り上げられている国は、サウジアラビア、南アフリカ、UAE、イスラエル、クウェート、エジプト、およびその他の中東およびアフリカの国々です。
中東およびアフリカは、IgA腎症製品の需要が高まっているため、IgA腎症の需要が高まっているため、予測期間中に最も速いCAGRで成長すると予想されています。サウジアラビアは、高度なIgA腎症製品とサービスを活用する中東およびアフリカの主要国の一つであるため、中東およびアフリカのIgA腎症市場を支配すると予想されています。
レポートの国別セクションでは、市場の現在および将来の傾向に影響を与える国内市場における個別の市場影響要因と規制の変更も提供しています。新規販売、交換販売、国の人口統計、規制行為、輸出入関税などのデータ ポイントは、各国の市場シナリオを予測するために使用される主要な指標の一部です。また、中東およびアフリカのブランドの存在と可用性、および地元および国内ブランドとの競争が激しいか少ないために直面する課題、販売チャネルの影響を考慮しながら、国別データの予測分析を提供します。
メーカーによる戦略的取り組みは、IgA腎症市場のプレーヤーに新たな機会を生み出しています。
IgA 腎症市場では、各国の成長に関する詳細な市場分析も提供しています。さらに、中東およびアフリカ地域の IgA 腎症市場プレーヤー間の IgA 腎症の売上、パートナーシップ、買収、販売契約の成長に関する詳細なデータも提供しています。データは 2011 年から 2019 年までの履歴期間について利用可能です。
競争環境とIgA腎症の市場シェア分析
IgA 腎症市場の競争状況では、競合他社ごとに詳細が提供されます。詳細には、会社概要、会社の財務状況、収益、市場の可能性、研究開発への投資、新しい市場への取り組み、生産拠点と施設、会社の強みと弱み、製品の発売、製品試験パイプライン、製品の承認、特許、製品の幅と広さ、アプリケーションの優位性、技術ライフライン曲線が含まれます。提供されている上記のデータ ポイントは、中東およびアフリカの IgA 腎症市場に関連する会社の焦点にのみ関連しています。
中東およびアフリカの IgA 腎症市場レポートで取り上げられている主なプレーヤーは、AstraZeneca、Novartis AG、Pfizer Inc.、Zydus Cadila、Fresenius Kabi USA (Fresenius SE & Co. KGaA の子会社)、Teva Pharmaceuticals USA, Inc. (Teva Pharmaceutical Industries Ltd. の子会社)、Hikma Pharmaceuticals PLC、LUPIN、Siemens Healthcare GmBH (Siemens Healthineers AG の子会社)、Sun Pharmaceutical Industries Ltd.、ARKRAY USA, Inc.、Merck Sharp & Dohme Corp. (Merck & Co., Inc. の子会社)、CareDX, Inc.、Alembic Pharmaceuticals Limited、Strides Pharma Science Limited、Apotex Inc. など国内プレーヤーです。DBMR アナリストは、競争力を理解し、各競合他社の競合分析を個別に提供します。
世界中の企業によって多くの契約や協定も開始されており、これもIgA腎症市場の拡大を加速させています。
例えば、
- 2020年9月、LUPINは、成人および10歳以上の小児のコレステロールを下げるために使用される10mg/20mg/40mgおよび80mgのアトルバスタチンカルシウム錠USPの発売を発表しました。この製品の発売により、同社は収益の増加に役立っています。
市場プレーヤーによるコラボレーション、ジョイントベンチャー、その他の戦略により、IgA腎症市場における企業の印象が強化され、組織にとってもIgA腎症の売上成長を向上させるメリットがもたらされます。
SKU-
世界初のマーケットインテリジェンスクラウドに関するレポートにオンラインでアクセスする
- インタラクティブなデータ分析ダッシュボード
- 成長の可能性が高い機会のための企業分析ダッシュボード
- カスタマイズとクエリのためのリサーチアナリストアクセス
- インタラクティブなダッシュボードによる競合分析
- 最新ニュース、更新情報、トレンド分析
- 包括的な競合追跡のためのベンチマーク分析のパワーを活用
目次
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF MIDDLE EAST AND AFRICA IGA NEPHROPATHY MARKET
1.4 LIMITATIONS
1.5 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 CURRENCY AND PRICING
2.5 DBMR TRIPOD DATA VALIDATION MODEL
2.6 MULTIVARIATE MODELLING
2.7 DISEASE TYPE LIFELINE CURVE
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.9 DBMR MARKET POSITION GRID
2.1 VENDOR SHARE ANALYSIS
2.11 MARKET END USER COVERAGE GRID
2.12 SECONDARY SOURCES
2.13 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 PREMIUM INSIGHTS
4.1 PESTEL ANALYSIS
4.2 PORTER'S FIVE FORCES MODEL
4.3 CURRENT STUDIES ON ARCHAEOSOMES
5 MIDDLE EAST AND AFRICA IGA NEPHROPATHY MARKET: COMPETITIVE ENVIRONMENT
6 MIDDLE EAST AND AFRICA IGA NEPHROPATHY MARKET: REGULATIONS
6.1 THE U.S. REGULATORY FRAMEWORK FOR IGA NEPHROPATHY
6.2 EUROPE REGULATORY FRAMEWORK FOR IGA NEPHROPATHY
6.3 JAPAN REGULATORY FRAMEWORK FOR IGA NEPHROPATHY
7 EPIDEMIOLOGY
8 MARKET OVERVIEW
8.1 DRIVERS
8.1.1 MIDDLE EAST AND AFRICA RISE IN IGA NEPHROPATHY DISORDER
8.1.2 1.1.2 INCREASING IGA TARGETED PIPELINE DRUGS
8.1.3 INCREASE RESEARCH & DEVELOPMENT INVESTMENT FOR DRUG DISCOVERY
8.1.4 REIMBURSEMENT PROVIDED FOR KIDNEY DISORDERS
8.1.5 1.1.5 UPCOMING AND RECENT APPROVAL FOR IGA NEPHROPATHY TREATMENT
8.2 RESTRAINTS
8.2.1 HIGH COST OF IGA NEPHROPATHY TREATMENT
8.2.2 DELAYED DIAGNOSIS OF IGA DISORDERS
8.2.3 POOR PLANNING OF IGA NEPHROPATHY TREATMENT IN LOW-INCOME COUNTRIES
8.2.4 INABILITY TO STOP PROGRESSION OF IGA NEPHROPATHY BY CURRENT TREATMENT
8.3 OPPORTUNITIES
8.3.1 COLLABORATION OF MARKET PLAYERS FOR DRUG DEVELOPMENT
8.3.2 GOVERNMENT FUNDING FOR RESEARCH PURPOSE
8.3.3 INCREASE TREND FOR NOVEL DIAGNOSIS PROCEDURE
8.4 CHALLENGES
8.4.1 LOW AWARENESS REGARDING KIDNEY DISEASE
8.4.2 SIDE EFFECT IGA NEPHROPATHY TREATMENT DRUGS
9 IMPACT OF COVID 19 ON THE MIDDLE EAST AND AFRICA IGA NEPHROPATHY MARKET
9.1 IMPACT ON PRICE
9.2 IMPACT OF DEMAND:
9.3 IMPACT ON SUPPLY CHAIN:
9.4 STRATEGIC DECISIONS FOR MANUFACTURERS:
9.5 CONCLUSION:
10 MIDDLE EAST AND AFRICA IGA NEPHROPATHY MARKET, BY DISEASE TYPE
10.1 OVERVIEW
10.2 PRIMARY IGA NEPHROPATHY
10.3 SECONDARY IGA NEPHROPATHY
11 MIDDLE EAST AND AFRICA IGA NEPHROPATHY MARKET, BY SYMPTOMS
11.1 OVERVIEW
11.2 HEMATURIA
11.3 PROTEINURIA
11.4 EDEMA
11.5 OTHERS
12 MIDDLE EAST AND AFRICA IGA NEPHROPATHY MARKET, BY TYPE
12.1 OVERVIEW
12.2 DIAGNOSIS
12.2.1 URINE TEST
12.2.1.1 URINE ALBUMIN-TO-CREATININE RATIO
12.2.1.2 DIPSTICK TEST FOR ALBUMIN AND BLOOD
12.2.2 BLOOD TEST
12.2.3 IOTHALAMATE CLEARANCE TEST
12.2.4 KIDNEY BIOPSY
12.2.5 OTHERS
12.3 TREATMENT
12.3.1 BLOOD PRESSURE LOWERING AGENTS
12.3.1.1 ANGIOTENSIN-CONVERTING ENZYME (ACE) INHIBITORS
12.3.1.1.1 LISINOPRIL
12.3.1.1.2 ENALAPRIL
12.3.1.1.3 RAMIPRIL
12.3.1.1.4 BENAZEPRIL
12.3.1.1.5 OTHERS
12.3.1.2 ANGIOTENSIN RECEPTOR BLOCKERS (ARBS)
12.3.1.2.1 LOSARTAN
12.3.1.2.2 VALSARTAN
12.3.1.2.3 IRBESARTAN
12.3.1.2.4 OTHERS
12.3.2 IMMUNOSUPPRESANT
12.3.2.1 CYCLOPHOSPHAMIDE
12.3.2.2 AZATHIOPRINE
12.3.2.3 CORTICOSTEROIDS
12.3.2.3.1 METHYLPREDNISONE
12.3.2.3.2 PREDNISOLONE
12.3.2.3.3 OTHERS
12.3.2.4 OTHERS
12.3.3 DIURETICS
12.3.3.1 FUROSEMIDE
12.3.3.2 TORSEMIDE
12.3.3.3 BUMETANIDE
12.3.3.4 OTHERS
12.3.4 LOWER BLOOD CHOLESTEROL
12.3.4.1 ATROVASTATIN
12.3.4.2 SIMVASTATIN
12.3.4.3 ROSUVASTATIN
12.3.4.4 FLUVASTATIN
12.3.4.5 PRAVASTATIN
12.3.4.6 OTHERS
12.3.5 SUPPLEMENTS
12.3.5.1 OMEGA-3-FATTY ACIDS
12.3.5.2 VITAMIN E
12.3.5.3 OTHERS
12.3.6 OTHERS
13 MIDDLE EAST AND AFRICA IGA NEPHROPATHY MARKET, BY POPULATION TYPE
13.1 OVERVIEW
13.2 ADULTS
13.3 CHILDREN
14 MIDDLE EAST AND AFRICA IGA NEPHROPATHY MARKET, BY ROUTE OF ADMINISTRATION
14.1 OVERVIEW
14.2 ORAL
14.2.1 TABLETS/PILLS
14.2.2 CAPSULES
14.2.3 OTHERS
14.3 PARENTERAL
14.3.1 INTRAVENOUS
14.3.2 INTRAMUSCULAR
14.3.3 OTHERS
14.4 OTHERS
15 MIDDLE EAST AND AFRICA IGA NEPHROPATHY MARKET, BY END USER
15.1 OVERVIEW
15.2 HOSPITALS
15.3 CLINICS
15.4 HOME HEALTHCARE
15.5 OTHERS
16 MIDDLE EAST AND AFRICA IGA NEPHROPATHY MARKET, BY DISTRIBUTION CHANNEL
16.1 OVERVIEW
16.2 HOSPITAL PHARMACY
16.3 RETAIL PHARMACY
16.4 ONLINE PHARMACY
16.5 DIRECT TENDER
16.6 OTHERS
17 MIDDLE EAST AND AFRICA IGA NEPHROPATHY MARKET BY GEOGRAPHY
17.1 MIDDLE EAST & AFRICA
17.1.1 SAUDI ARABIA
17.1.2 SOUTH AFRICA
17.1.3 ISRAEL
17.1.4 ISRAEL
17.1.5 KUWAIT
17.1.6 EGYPT
17.1.7 REST OF MIDDLE EAST & AFRICA
18 MIDDLE EAST AND AFRICA IGA NEPHROPATHY MARKET: COMPANY LANDSCAPE
18.1 COMPANY SHARE ANALYSIS: MIDDLE EAST AND AFRICA
19 SWOT
20 COMPANY PROFILES
20.1 VIATRIS INC.
20.1.1 COMPANY SNAPSHOT
20.1.2 REVENUE ANALYSIS
20.1.3 COMPANY SHARE ANALYSIS
20.1.4 PRODUCT PORTFOLIO
20.1.5 RECENT DEVELOPMENTS
20.2 TEVA PHARMACEUTICAL USA, INC. (A SUBSIDIARY OF TEVA PHARMACEUTICAL INDUSTRIES LTD.)
20.2.1 COMPANY SNAPSHOT
20.2.2 REVENUE FINANCIALS
20.2.3 COMPANY SHARE ANALYSIS
20.2.4 PRODUCT PORTFOLIO
20.2.5 RECENT DEVELOPMENTS
20.3 LUPIN
20.3.1 COMPANY SNAPSHOT
20.3.2 REVENUE FINANCIALS
20.3.3 COMPANY SHARE ANALYSIS
20.3.4 PRODUCT PORTFOLIO
20.3.5 RECENT DEVELOPMENTS
20.4 ACCORD HEALTHCARE
20.4.1 COMPANY SNAPSHOT
20.4.2 COMPANY SHARE ANALYSIS
20.4.3 PRODUCT PORTFOLIO
20.4.4 RECENT DEVELOPMENTS
20.5 ASTRAZENECA
20.5.1 COMPANY SNAPSHOT
20.5.2 RECENT FINANCIALS
20.5.3 PRODUCT PORTFOLIO
20.5.4 RECENT DEVELOPMENTS
20.6 PFIZER INC.
20.6.1 COMPANY SNAPSHOT
20.6.2 REVENUE FINANCIALS
20.6.3 PRODUCT PORTFOLIO
20.6.4 RECENT DEVELOPMENTS
20.7 ZYDUS CADILLA
20.7.1 COMPANY SNAPSHOT
20.7.2 REVENUE FINANCIALS
20.7.3 PRODUCT PORTFOLIO
20.7.4 RECENT DEVELOPMENTS
20.8 NOVARTIS AG
20.8.1 COMPANY SNAPSHOT
20.8.2 REVENUE FINANCIALS
20.8.3 PRODUCT PORTFOLIO
20.8.4 RECENT DEVELOPMENTS
20.9 ALEMBIC PHARMACEUTICALS LIMITED
20.9.1 COMPANY SNAPSHOT
20.9.2 REVENUE ANALYSIS
20.9.3 PRODUCT PORTFOLIO
20.9.4 RECENT DEVELOPMENTS
20.1 STRIDES PHARMA SCIENCE LIMITED
20.10.1 COMPANY SNAPSHOT
20.10.2 REVENUE FINANCIALS
20.10.3 PRODUCT PORTFOLIO
20.10.4 RECENT DEVELOPMENTS
20.11 SIEMENS HEALTHCARE GMBH (A SUBSIDIARY OF SIEMENS HEALTHINEERS AG)
20.11.1 COMPANY SNAPSHOT
20.11.2 REVENUE FINANCIALS
20.11.3 PRODUCT PORTFOLIO
20.11.4 RECENT DEVELOPMENTS
20.12 MERCK SHARP & DOHME CORP., A SUBSIDIARY OF MERCK & CO., INC.
20.12.1 COMPANY SNAPSHOT
20.12.2 REVENUE ANALYSIS
20.12.3 PRODUCT PORTFOLIO
20.12.4 RECENT DEVELOPMENTS
20.13 HIKMA PHARMACEUTICALS PLC
20.13.1 COMPANY SNAPSHOT
20.13.2 REVENUE ANALYSIS
20.13.3 PRODUCT PORTFOLIO
20.13.4 RECENT DEVELOPMENTS
20.14 SUN PHARMACEUTICAL INDUSTRIES LTD.
20.14.1 COMPANY SNAPSHOT
20.14.2 REVENUE FINANCIALS
20.14.3 PRODUCT PORTFOLIO
20.14.4 RECENT DEVELOPMENT
20.15 APOTEX INC.
20.15.1 COMPANY SNAPSHOT
20.15.2 PRODUCT PORTFOLIO
20.15.3 RECENT DEVELOPMENTS
20.16 ARKRAY USA, INC.
20.16.1 COMPANY SNAPSHOT
20.16.2 PRODUCT PORTFOLIO
20.16.3 RECENT DEVELOPMENTS
20.17 CALIDITAS THERAPEUTICS AB
20.17.1 COMPANY SNAPSHOT
20.17.2 REVENUE FINANCIALS
20.17.3 PRODUCT PORTFOLIO
20.17.4 RECENT DEVELOPMENTS
20.18 CAREDX, INC.
20.18.1 COMPANY SNAPSHOT
20.18.2 REVENUE ANALYSIS
20.18.3 PRODUCT PORTFOLIO
20.18.4 RECENT DEVELOPMENTS
20.19 FRESENIUS KABI USA (A SUBSIDIARY OF FRESENIUS SE & CO. KGAA)
20.19.1 COMPANY SNAPSHOT
20.19.2 REVENUE FINANCIALS
20.19.3 PRODUCT PORTFOLIO
20.19.4 RECENT DEVELOPMENTS
20.2 OMEROS CORPORATION
20.20.1 COMPANY SNAPSHOT
20.20.2 REVENUE ANALYSIS
20.20.3 PRODUCT PORTFOLIO
20.20.4 RECENT DEVELOPMENTS
21 QUESTIONNAIRE
22 RELATED REPORTS
表のリスト
TABLE 1 MIDDLE EAST AND AFRICA IGA NEPHROPATHY MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)
TABLE 2 MIDDLE EAST AND AFRICA PRIMARY IGA NEPHROPATHY IN IGA NEPHROPATHY MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)
TABLE 3 MIDDLE EAST AND AFRICA SECONDARY IGA NEPHROPATHY IN IGA NEPHROPATHY MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)
TABLE 4 MIDDLE EAST AND AFRICA IGA NEPHROPATHY MARKET, BY SYMPTOMS, 2019-2028 (USD MILLION)
TABLE 5 MIDDLE EAST AND AFRICA HEMATURIA IN IGA NEPHROPATHY MARKET, BY SYMPTOMS, 2019-2028 (USD MILLION)
TABLE 6 MIDDLE EAST AND AFRICA PROTEINURIA IN IGA NEPHROPATHY MARKET, BY SYMPTOMS, 2019-2028 (USD MILLION)
TABLE 7 MIDDLE EAST AND AFRICA EDEMA IN IGA NEPHROPATHY MARKET, BY SYMPTOMS, 2019-2028 (USD MILLION)
TABLE 8 MIDDLE EAST AND AFRICA OTHERS IN IGA NEPHROPATHY MARKET, BY SYMPTOMS, 2019-2028 (USD MILLION)
TABLE 9 MIDDLE EAST AND AFRICA IGA NEPHROPATHY MARKET, BY PRODUCT TYPE, 2019-2028 (USD MILLION)
TABLE 10 MIDDLE EAST AND AFRICA DIAGNOSIS IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 11 MIDDLE EAST AND AFRICA DIAGNOSIS IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 12 MIDDLE EAST AND AFRICA URINE TEST IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 13 MIDDLE EAST AND AFRICA TREATMENT IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 14 MIDDLE EAST AND AFRICA TREATMENT IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 15 MIDDLE EAST AND AFRICA TREATMENT BY BLOOD PRESSURE LOWERING AGENTS IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 16 MIDDLE EAST AND AFRICA TREATMENT BY ACE-INHIBITOR IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 17 MIDDLE EAST AND AFRICA TREATMENT BY ANGIOTENSIN RECEPTOR BLOCKERS IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 18 MIDDLE EAST AND AFRICA TREATMENT BY IMMUNOSUPPRESSANT IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 19 MIDDLE EAST AND AFRICA TREATMENT BY CORTICOSTEROIDS IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 20 MIDDLE EAST AND AFRICA TREATMENT BY DIURETICS IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 21 MIDDLE EAST AND AFRICA TREATMENT BY DIURETICS IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 22 MIDDLE EAST AND AFRICA TREATMENT BY SUPPLEMENTS IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 23 MIDDLE EAST AND AFRICA IGA NEPHROPATHY MARKET, BY POPULATION TYPE, 2019-2028 (USD MILLION)
TABLE 24 MIDDLE EAST AND AFRICA ADUTLS IN IGA NEPHROPATHY MARKET, BY POPULATION TYPE, 2019-2028 (USD MILLION)
TABLE 25 MIDDLE EAST AND AFRICA CHILDREN IN IGA NEPHROPATHY MARKET, BY POPULATION TYPE, 2019-2028 (USD MILLION)
TABLE 26 MIDDLE EAST AND AFRICA IGA NEPHROPATHY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 27 MIDDLE EAST AND AFRICA ORAL ADMINISTRATION IN IGA NEPHROPATHY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 28 MIDDLE EAST AND AFRICA ORAL ADMINISTRATION IN IGA NEPHROPATHY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 29 MIDDLE EAST AND AFRICA PARENTERAL IN IGA NEPHROPATHY MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 30 MIDDLE EAST AND AFRICA PARENTERAL ADMINISTRATION IN IGA NEPHROPATHY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 31 MIDDLE EAST AND AFRICA OTHERS IN IGA NEPHROPATHY MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 32 MIDDLE EAST AND AFRICA IGA NEPHROPATHY MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 33 MIDDLE EAST AND AFRICA HOSPITALS IN IGA NEPHROPATHY MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 34 SPECIALTY CLINICS IN IGA NEPHROPATHY MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 35 MIDDLE EAST AND AFRICA HOME HEALTHCARE IN IGA NEPHROPATHY MARKET, BY REGION, 20190-2028 (USD MILLION)
TABLE 36 MIDDLE EAST AND AFRICA OTHERS IN IGA NEPHROPATHY MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 37 MIDDLE EAST AND AFRICA IGA NEPHROPATHY MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 38 MIDDLE EAST AND AFRICA HOPSITAL PHARMACY IN IGA NEPHROPATHY MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 39 MIDDLE EAST AND AFRICA RETAIL PHARMACY IN IGA NEPHROPATHY MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 40 MIDDLE EAST AND AFRICA ONLINE PARMACY IN IGA NEPHROPATHY MARKET, BY REGION, 2017-2028 (USD MILLION)
TABLE 41 MIDDLE EAST AND AFRICA DIRECT TENDER IN IGA NEPHROPATHY MARKET, BY REGION, 2018-2028 (USD MILLION)
TABLE 42 MIDDLE EAST AND AFRICA OTHERS IN IGA NEPHROPATHY MARKET, BY REGION, 2018-2028 (USD MILLION)
TABLE 43 MIDDLE EAST & AFRICA IGA NEPHROPATHY MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 44 MIDDLE EAST & AFRICA IGA NEPHROPATHY MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)
TABLE 45 MIDDLE EAST & AFRICA IGA NEPHROPATHY MARKET, BY SYMPTOMS, 2019-2028 (USD MILLION)
TABLE 46 MIDDLE EAST & AFRICA IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 47 MIDDLE EAST & AFRICA DIAGNOSIS IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 48 MIDDLE EAST & AFRICA DIAGNOSIS BY URINE TESTS IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 49 MIDDLE EAST & AFRICA TREATMENT IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 50 MIDDLE EAST & AFRICA TREATMENT BY BLOOD PRESSURE LOWERING AGENTS IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 51 MIDDLE EAST & AFRICA TREATMENT BY ACE-INHIBITOR IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 52 MIDDLE EAST & AFRICA TREATMENT BY ANGIOTENSIN RECEPTOR BLOCKERS IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 53 MIDDLE EAST & AFRICA TREATMENT BY IMMUNOSUPPRESSAN IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 54 MIDDLE EAST & AFRICA TREATMENT BY CORTICOSTEROIDS IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 55 MIDDLE EAST & AFRICA TREATMENT BY DIURETICS IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 56 MIDDLE EAST & AFRICA TREATMENT BY LOWER BLOOD CHOLESTEROL AGENTS IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 57 MIDDLE EAST & AFRICA TREATMENT BY SUPPLEMENTS IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 58 MIDDLE EAST & AFRICA IGA NEPHROPATHY MARKET, BY POPULATION, 2019-2028 (USD MILLION)
TABLE 59 MIDDLE EAST & AFRICA IGA NEPHROPATHY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 60 MIDDLE EAST & AFRICA ORAL ADMINISTRATION IN IGA NEPHROPATHY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 61 MIDDLE EAST & AFRICA PARENTERAL ADMINISTRATION IN IGA NEPHROPATHY MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 62 MIDDLE EAST & AFRICA IGA NEPHROPATHY MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 63 MIDDLE EAST & AFRICA IGA NEPHROPATHY MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 64 SAUDI ARABIA IGA NEPHROPATHY MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)
TABLE 65 SAUDI ARABIA IGA NEPHROPATHY MARKET, BY SYMPTOMS, 2019-2028 (USD MILLION)
TABLE 66 SAUDI ARABIA IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 67 SAUDI ARABIA DIAGNOSIS IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 68 SAUDI ARABIA DIAGNOSIS BY URINE TESTS IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 69 SAUDI ARABIA TREATMENT IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 70 SAUDI ARABIA TREATMENT BY BLOOD PRESSURE LOWERING AGENTS IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 71 SAUDI ARABIA TREATMENT BY ACE-INHIBITOR IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 72 SAUDI ARABIA TREATMENT BY ANGIOTENSIN RECEPTOR BLOCKERS IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 73 SAUDI ARABIA TREATMENT BY IMMUNOSUPPRESSAN IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 74 SAUDI ARABIA TREATMENT BY CORTICOSTEROIDS IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 75 SAUDI ARABIA IGA TREATMENT BY DIURETICS IN NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 76 SAUDI ARABIA TREATMENT BY LOWER BLOOD CHOLESTEROL AGENTS IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 77 SAUDI ARABIA TREATMENT BY SUPPLEMENTS IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 78 SAUDI ARABIA IGA NEPHROPATHY MARKET, BY POPULATION, 2019-2028 (USD MILLION)
TABLE 79 SAUDI ARABIA IGA NEPHROPATHY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 80 SAUDI ARABIA ORAL ADMINISTRATION IN IGA NEPHROPATHY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 81 SAUDI ARABIA PARENTERAL ADMINISTRATION IN IGA NEPHROPATHY MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 82 SAUDI ARABIA IGA NEPHROPATHY MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 83 SAUDI ARABIA IGA NEPHROPATHY MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 84 SOUTH AFRICA IGA NEPHROPATHY MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)
TABLE 85 SOUTH AFRICA IGA NEPHROPATHY MARKET, BY SYMPTOMS, 2019-2028 (USD MILLION)
TABLE 86 SOUTH AFRICA IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 87 SOUTH AFRICA DIAGNOSIS IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 88 SOUTH AFRICA DIAGNOSIS BY URINE TESTS IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 89 SOUTH AFRICA TREATMENT IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 90 SOUTH AFRICA TREATMENT BY BLOOD PRESSURE LOWERING AGENTS IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 91 SOUTH AFRICA TREATMENT BY ACE-INHIBITOR IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 92 SOUTH AFRICA TREATMENT BY ANGIOTENSIN RECEPTOR BLOCKERS IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 93 SOUTH AFRICA TREATMENT BY IMMUNOSUPPRESSAN IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 94 SOUTH AFRICA TREATMENT BY CORTICOSTEROIDS IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 95 SOUTH AFRICA TREATMENT BY DIURETICS IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 96 SOUTH AFRICA TREATMENT BY LOWER BLOOD CHOLESTEROL AGENTS IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 97 SOUTH AFRICA TREATMENT BY SUPPLEMENTS IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 98 SOUTH AFRICA IGA NEPHROPATHY MARKET, BY POPULATION, 2019-2028 (USD MILLION)
TABLE 99 SOUTH AFRICA IGA NEPHROPATHY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 100 SOUTH AFRICA ORAL ADMINISTRATION IN IGA NEPHROPATHY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 101 SOUTH AFRICA PARENTERAL ADMINISTRATION IN IGA NEPHROPATHY MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 102 SOUTH AFRICA IGA NEPHROPATHY MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 103 SOUTH AFRICA IGA NEPHROPATHY MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 104 ISRAEL IGA NEPHROPATHY MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)
TABLE 105 ISRAEL IGA NEPHROPATHY MARKET, BY SYMPTOMS, 2019-2028 (USD MILLION)
TABLE 106 ISRAEL IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 107 ISRAEL DIAGNOSIS IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 108 ISRAEL DIAGNOSIS BY URINE TESTS IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 109 ISRAEL TREATMENT IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 110 ISRAEL TREATMENT BY BLOOD PRESSURE LOWERING AGENTS IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 111 ISRAEL TREATMENT BY ACE-INHIBITOR IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 112 ISRAEL TREATMENT BY ANGIOTENSIN RECEPTOR BLOCKERS IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 113 ISRAEL TREATMENT BY IMMUNOSUPPRESSAN IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 114 ISRAEL TREATMENT BY CORTICOSTEROIDS IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 115 ISRAEL TREATMENT BY DIURETICS IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 116 ISRAEL TREATMENT BY LOWER BLOOD CHOLESTEROL AGENTS IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 117 ISRAEL TREATMENT BY SUPPLEMENTS IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 118 ISRAEL IGA NEPHROPATHY MARKET, BY POPULATION, 2019-2028 (USD MILLION)
TABLE 119 ISRAEL IGA NEPHROPATHY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 120 ISRAEL ORAL ADMINISTRATION IN IGA NEPHROPATHY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 121 ISRAEL PARENTERAL ADMINISTRATION IN IGA NEPHROPATHY MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 122 ISRAEL IGA NEPHROPATHY MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 123 ISRAEL IGA NEPHROPATHY MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 124 ISRAEL IGA NEPHROPATHY MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)
TABLE 125 ISRAEL IGA NEPHROPATHY MARKET, BY SYMPTOMS, 2019-2028 (USD MILLION)
TABLE 126 ISRAEL IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 127 ISRAEL DIAGNOSIS IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 128 ISRAELDIAGNOSIS BY URINE TESTS IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 129 ISRAEL TREATMENT IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 130 ISRAEL TREATMENT BY BLOOD PRESSURE LOWERING AGENTS IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 131 ISRAEL TREATMENT BY ACE-INHIBITOR IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 132 ISRAEL TREATMENT BY ANGIOTENSIN RECEPTOR BLOCKERS IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 133 ISRAEL TREATMENT BY IMMUNOSUPPRESSAN IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 134 ISRAEL TREATMENT BY CORTICOSTEROIDS IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 135 ISRAEL TREATMENT BY DIURETICS IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 136 ISRAEL TREATMENT BY LOWER BLOOD CHOLESTEROL AGENTS IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 137 ISRAEL TREATMENT BY SUPPLEMENTS IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 138 ISRAEL IGA NEPHROPATHY MARKET, BY POPULATION, 2019-2028 (USD MILLION)
TABLE 139 ISRAEL IGA NEPHROPATHY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 140 ISRAEL ORAL ADMINISTRATION IN IGA NEPHROPATHY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 141 ISRAEL PARENTERAL ADMINISTRATION IN IGA NEPHROPATHY MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 142 ISRAEL IGA NEPHROPATHY MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 143 ISRAEL IGA NEPHROPATHY MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 144 KUWAIT IGA NEPHROPATHY MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)
TABLE 145 KUWAIT IGA NEPHROPATHY MARKET, BY SYMPTOMS, 2019-2028 (USD MILLION)
TABLE 146 KUWAIT IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 147 KUWAIT DIAGNOSIS IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 148 KUWAITDIAGNOSIS BY URINE TESTS IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 149 KUWAIT TREATMENT IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 150 KUWAIT TREATMENT BY BLOOD PRESSURE LOWERING AGENTS IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 151 KUWAIT TREATMENT BY ACE-INHIBITOR IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 152 KUWAIT TREATMENT BY ANGIOTENSIN RECEPTOR BLOCKERS IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 153 KUWAIT TREATMENT BY IMMUNOSUPPRESSAN IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 154 KUWAIT TREATMENT BY CORTICOSTEROIDS IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 155 KUWAIT TREATMENT BY DIURETICS IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 156 KUWAIT TREATMENT BY LOWER BLOOD CHOLESTEROL AGENTS IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 157 KUWAIT TREATMENT BY SUPPLEMENTS IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 158 KUWAIT IGA NEPHROPATHY MARKET, BY POPULATION, 2019-2028 (USD MILLION)
TABLE 159 KUWAIT IGA NEPHROPATHY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 160 KUWAIT ORAL ADMINISTRATION IN IGA NEPHROPATHY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 161 KUWAIT PARENTERAL ADMINISTRATION IN IGA NEPHROPATHY MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 162 KUWAIT IGA NEPHROPATHY MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 163 KUWAIT IGA NEPHROPATHY MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 164 EGYPT IGA NEPHROPATHY MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)
TABLE 165 EGYPT IGA NEPHROPATHY MARKET, BY SYMPTOMS, 2019-2028 (USD MILLION)
TABLE 166 EGYPT IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 167 EGYPT DIAGNOSIS IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 168 EGYPTDIAGNOSIS BY URINE TESTS IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 169 EGYPT TREATMENT IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 170 EGYPT TREATMENT BY BLOOD PRESSURE LOWERING AGENTS IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 171 EGYPT TREATMENT BY ACE-INHIBITOR IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 172 EGYPT TREATMENT BY ANGIOTENSIN RECEPTOR BLOCKERS IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 173 EGYPT TREATMENT BY IMMUNOSUPPRESSAN IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 174 EGYPT TREATMENT BY CORTICOSTEROIDS IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 175 EGYPT TREATMENT BY DIURETICS IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 176 EGYPT TREATMENT BY LOWER BLOOD CHOLESTEROL AGENTS IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 177 EGYPT TREATMENT BY SUPPLEMENTS IN IGA NEPHROPATHY MARKET, BY TYPE, 2019-2028 (USD MILLION)
TABLE 178 EGYPT IGA NEPHROPATHY MARKET, BY POPULATION, 2019-2028 (USD MILLION)
TABLE 179 EGYPT IGA NEPHROPATHY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 180 EGYPT ORAL ADMINISTRATION IN IGA NEPHROPATHY MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 181 EGYPT PARENTERAL ADMINISTRATION IN IGA NEPHROPATHY MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 182 EGYPT IGA NEPHROPATHY MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 183 EGYPT IGA NEPHROPATHY MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 184 REST OF MIDDLE EAST & AFRICA IGA NEPHROPATHY MARKET, BY DISEASE TYPE, 2019-2028 (USD MILLION)
図表一覧
FIGURE 1 MIDDLE EAST AND AFRICA IGA NEPHROPATHY MARKET: SEGMENTATION
FIGURE 2 MIDDLE EAST AND AFRICA IGA NEPHROPATHY MARKET: DATA TRIANGULATION
FIGURE 3 MIDDLE EAST AND AFRICA IGA NEPHROPATHY MARKET: DROC ANALYSIS
FIGURE 4 MIDDLE EAST AND AFRICA IGA NEPHROPATHY MARKET: MIDDLE EAST AND AFRICA VS REGIONAL MARKET ANALYSIS
FIGURE 5 MIDDLE EAST AND AFRICA IGA NEPHROPATHY MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 MIDDLE EAST AND AFRICA IGA NEPHROPATHY MARKET: MULTIVARIATE MODELLING
FIGURE 7 MIDDLE EAST AND AFRICA IGA NEPHROPATHY MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 8 MIDDLE EAST AND AFRICA IGA NEPHROPATHY MARKET: DBMR MARKET POSITION GRID
FIGURE 9 MIDDLE EAST AND AFRICA IGA NEPHROPATHY MARKET: VENDOR SHARE ANALYSIS
FIGURE 10 MIDDLE EAST AND AFRICA IGA NEPHROPATHY MARKET: MARKET END USER COVERAGE GRID
FIGURE 11 MIDDLE EAST AND AFRICA IGA NEPHROPATHY MARKET: SEGMENTATION
FIGURE 12 MIDDLE EAST AND AFRICA RISE IN IGA NEPHROPATHY DISORDER IS DRIVING THE MIDDLE EAST AND AFRICA IGA NEPHROPATHY MARKET IN THE FORECAST PERIOD OF 2021 TO 2028
FIGURE 13 PRIMARY IGA NEPHROPATHY SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE MIDDLE EAST AND AFRICA IGA NEPHROPATHY MARKET IN 2021 & 2028
FIGURE 14 DRIVERS, RESTRAINTS, OPPORTUNITIES AND CHALLENGES OF MIDDLE EAST AND AFRICA IGA NEPHROPATHY MARKET
FIGURE 15 IGA NEPHROPATHY BIOPSIES IN DIFFERENT REGIONS
FIGURE 16 MIDDLE EAST AND AFRICA IGA NEPHROPATHY MARKET: BY DISEASE TYPE, 2020
FIGURE 17 MIDDLE EAST AND AFRICA IGA NEPHROPATHY MARKET: BY DISEASE TYPE, 2020-2028 (USD MILLION)
FIGURE 18 MIDDLE EAST AND AFRICA IGA NEPHROPATHY MARKET: BY DISEASE TYPE, CAGR (2020-2028)
FIGURE 19 MIDDLE EAST AND AFRICA IGA NEPHROPATHY MARKET: BY DISEASE TYPE, LIFELINE CURVE
FIGURE 20 MIDDLE EAST AND AFRICA IGA NEPHROPATHY MARKET: BY SYMPTOMS, 2020
FIGURE 21 MIDDLE EAST AND AFRICA IGA NEPHROPATHY MARKET: BY SYMPTOMS, 2020-2028 (USD MILLION)
FIGURE 22 MIDDLE EAST AND AFRICA IGA NEPHROPATHY MARKET: BY SYMPTOMS, CAGR (2020-2028)
FIGURE 23 MIDDLE EAST AND AFRICA IGA NEPHROPATHY MARKET: BY SYMPTOMS, LIFELINE CURVE
FIGURE 24 MIDDLE EAST AND AFRICA IGA NEPHROPATHY MARKET: BY TYPE, 2020
FIGURE 25 MIDDLE EAST AND AFRICA IGA NEPHROPATHY MARKET: BY TYPE, 2020-2028 (USD MILLION)
FIGURE 26 MIDDLE EAST AND AFRICA IGA NEPHROPATHY MARKET: BY TYPE, CAGR (2020-2028)
FIGURE 27 MIDDLE EAST AND AFRICA IGA NEPHROPATHY MARKET: BY TYPE, LIFELINE CURVE
FIGURE 28 MIDDLE EAST AND AFRICA IGA NEPHROPATHY MARKET: BY POPULATION TYPE, 2020
FIGURE 29 MIDDLE EAST AND AFRICA IGA NEPHROPATHY MARKET: BY POPULATION TYPE, 2020-2028 (USD MILLION)
FIGURE 30 MIDDLE EAST AND AFRICA IGA NEPHROPATHY MARKET: BY POPULATION TYPE, CAGR (2020-2028)
FIGURE 31 MIDDLE EAST AND AFRICA IGA NEPHROPATHY MARKET: BY POPULATION TYPE, LIFELINE CURVE
FIGURE 32 MIDDLE EAST AND AFRICA IGA NEPHROPATHY MARKET: BY ROUTE OF ADMINISTRATION, 2020
FIGURE 33 MIDDLE EAST AND AFRICA IGA NEPHROPATHY MARKET: BY ROUTE OFADMINISTRATION, 2020-2028 (USD MILLION)
FIGURE 34 MIDDLE EAST AND AFRICA IGA NEPHROPATHY MARKET: BY ROUTE OF ADMINISTRATION, CAGR (2020-2028)
FIGURE 35 MIDDLE EAST AND AFRICA IGA NEPHROPATHY MARKET: BY ROUTE OF ADMINISTRATION, LIFELINE CURVE
FIGURE 36 MIDDLE EAST AND AFRICA IGA NEPHROPATHY MARKET: BY END USER, 2020
FIGURE 37 MIDDLE EAST AND AFRICA IGA NEPHROPATHY MARKET: BY END USER , 2020-2028 (USD MILLION)
FIGURE 38 MIDDLE EAST AND AFRICA IGA NEPHROPATHY MARKET: BY END USER, CAGR (2020-2028)
FIGURE 39 MIDDLE EAST AND AFRICA IGA NEPHROPATHY MARKET: BY END USER, LIFELINE CURVE
FIGURE 40 MIDDLE EAST AND AFRICA IGA NEPHROPATHY MARKET: BY DISTRIBUTION CHANNEL, 2020
FIGURE 41 MIDDLE EAST AND AFRICA IGA NEPHROPATHY MARKET: BY DISTRIBUTION CHANNEL, 2020-2028 (USD MILLION)
FIGURE 42 MIDDLE EAST AND AFRICA IGA NEPHROPATHY MARKET: BY DISTRIBUTION CHANNEL, CAGR (2020-2028)
FIGURE 43 MIDDLE EAST AND AFRICA IGA NEPHROPATHY MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 44 MIDDLE EAST & AFRICA IGA NEPHROPATHY MARKET: SNAPSHOT (2020)
FIGURE 45 MIDDLE EAST & AFRICA IGA NEPHROPATHY MARKET: BY COUNTRY (2020)
FIGURE 46 MIDDLE EAST & AFRICA IGA NEPHROPATHY MARKET: BY COUNTRY (2021 & 2028)
FIGURE 47 MIDDLE EAST & AFRICA IGA NEPHROPATHY MARKET: BY COUNTRY (2020 & 2028)
FIGURE 48 MIDDLE EAST & AFRICA IGA NEPHROPATHY MARKET: BY DISEASE TYPE (2021-2028)
FIGURE 49 MIDDLE EAST AND AFRICA IGA NEPHROPATHY MARKET: COMPANY SHARE 2020 (%)
調査方法
データ収集と基準年分析は、大規模なサンプル サイズのデータ収集モジュールを使用して行われます。この段階では、さまざまなソースと戦略を通じて市場情報または関連データを取得します。過去に取得したすべてのデータを事前に調査および計画することも含まれます。また、さまざまな情報ソース間で見られる情報の不一致の調査も含まれます。市場データは、市場統計モデルと一貫性モデルを使用して分析および推定されます。また、市場シェア分析と主要トレンド分析は、市場レポートの主要な成功要因です。詳細については、アナリストへの電話をリクエストするか、お問い合わせをドロップダウンしてください。
DBMR 調査チームが使用する主要な調査方法は、データ マイニング、データ変数が市場に与える影響の分析、および一次 (業界の専門家) 検証を含むデータ三角測量です。データ モデルには、ベンダー ポジショニング グリッド、市場タイムライン分析、市場概要とガイド、企業ポジショニング グリッド、特許分析、価格分析、企業市場シェア分析、測定基準、グローバルと地域、ベンダー シェア分析が含まれます。調査方法について詳しくは、お問い合わせフォームから当社の業界専門家にご相談ください。
カスタマイズ可能
Data Bridge Market Research は、高度な形成的調査のリーダーです。当社は、既存および新規のお客様に、お客様の目標に合致し、それに適したデータと分析を提供することに誇りを持っています。レポートは、対象ブランドの価格動向分析、追加国の市場理解 (国のリストをお問い合わせください)、臨床試験結果データ、文献レビュー、リファービッシュ市場および製品ベース分析を含めるようにカスタマイズできます。対象競合他社の市場分析は、技術ベースの分析から市場ポートフォリオ戦略まで分析できます。必要な競合他社のデータを、必要な形式とデータ スタイルでいくつでも追加できます。当社のアナリスト チームは、粗い生の Excel ファイル ピボット テーブル (ファクト ブック) でデータを提供したり、レポートで利用可能なデータ セットからプレゼンテーションを作成するお手伝いをしたりすることもできます。
